TITLE

Generex Receives Patent for Buccal Delivery of Insulin

PUB. DATE
December 2006
SOURCE
BioPharm International;Dec2006, Vol. 19 Issue 12, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the acquisition of an Australian patent by Generex Biotechnology Corp. for its micellar system that delivers macromolecules through buccal lining. Excipients will form a spherical micelle of surfactant molecules which will shield the protein from digestion by buccal enzymes in the delivery system. According to Anna Gluskin, president and CEO, the primary motivation to develop the formulation was to improve patient compliance.
ACCESSION #
23506697

 

Related Articles

  • GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4 

    The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lynâ„¢ at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1...

  • Women CEOs Proving It: Glass Ceiling Can Break. Hollingsworth, Catherine // BioWorld Today;6/22/2009, Vol. 20 Issue 118, p1 

    The article offers insights from a number of women chief executive officers (CEO) about their successful careers in the biotechnology industry. Anna Gluskin of Generex Biotechnology cites some career highlights and admits to experiencing personal sacrifices such as a couple of divorces in her...

  • European patents for Generex.  // European Pharmaceutical Executive;Sep2007, p9 

    The article reports that the European Patent Office has granted the fourth European patent of Generex Biotechnology Corp. entitled "Proteinic Drug Delivery System Using Membrane Mimetics." The patent includes formulation and process claims for liposome pharmaceutical formulation, which was...

  • CLINIC ROUNDUP.  // BioWorld Today;2/13/2014, Vol. 25 Issue 30, p7 

    This section offers news briefs on clinical studies by biopharmaceutical companies as of February 13, 2014. Generex Biotechnology Corp. reported results from a phase II study of AE37 cancer vaccine for preventing relapse in breast cancer patients. Omeros Corp. reported that OMS824 achieved...

  • Spray On, Insulin Users, Spray On.  // Diabetes Health;Feb/Mar2007, Vol. 16 Issue 1, p29 

    The article announces that Oral-lyn, an insulin spray developed by Generex Biotechnology Corp., has received the 2006 Technology Award for Innovation in the field of diabetic therapies from Frost and Sullivan Co.

  • Learning to Weather a Storm. Looney, William // Pharmaceutical Executive;Aug2010, Vol. 30 Issue 8, p10 

    The article discusses various reports published within the issue, including one on the second annual review of the journal's corporate strategies to build patient compliance with medicines, one on the intense competition in the pharmaceutical industry and the Ipsos Health Survey among 58 senior...

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics